Early Development Global Capabilities

The partner you select for your early phase studies is critical in helping you achieve your overall development timeline efficiently and within budget. You need a CRO that has an established network of carefully selected sites centered around quality, medical safety and unparalleled expertise.

We understand the importance of selecting the right sites when executing Phase I studies, that is why each of our global facilities undergo a rigorous selection process including GCP audits and/or pre-selection assessment visits. We have executed master clinical service agreements or agreed to contract language with all our sites.

PPD’s global network of Phase I clinical sites offer access to a diverse pool of healthy volunteers and specialty populations across four continents. Many of our 29 strategically located facilities are located near hospitals and universities, allowing us access to hundreds of faculty members in fields such as pulmonology, anesthesiology and neurology. With over 100 studies awarded through our global network in the past five years, our areas of expertise include: renal impairment, hepatic impairment, Japanese Bridging, Chinese Bridging in China and NHV studies.

Overall Indications and Specialty Populations Through our Global Site Network

Overall Indications Include:

Specialty Populations Include:

Elderly

Ethnic Specialty Populations

Pediatrics

Postmenopausal Females

Smokers

Hepatic/Renal Impaired